US Stock MarketDetailed Quotes
VRAX Virax Biolabs
- 2.1000
- +0.3700+21.39%
Close Dec 27 16:00 ET
- 2.0400
- -0.0600-2.86%
Post 20:01 ET
9.12MMarket Cap-0.80P/E (TTM)
2.1800High1.6700Low946.42KVolume1.6700Open1.7300Pre Close1.81MTurnover24.74%Turnover RatioLossP/E (Static)4.34MShares8.999952wk High1.05P/B8.03MFloat Cap0.600052wk Low--Dividend TTM3.83MShs Float290.0000Historical High--Div YieldTTM29.48%Amplitude0.6000Historical Low1.9090Avg Price1Lot Size
Virax Biolabs Key Stats
Quarterly+Annual
YOY
| (FY)Mar 31, 2024 | (FY)Mar 31, 2023 | (FY)Mar 31, 2022 | (FY)Mar 31, 2021 | (FY)Mar 31, 2020 | |
|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | |||||
| Cash flow from continuing operating activities | -49.46%-6.25M | -416.61%-4.18M | -37.09%-809.07K | 20.74%-590.19K | -744.61K |
| Net income from continuing operations | -23.48%-6.74M | -211.90%-5.46M | -160.04%-1.75M | 9.00%-672.92K | ---739.46K |
| Operating gains losses | 97.01%-8.8K | -482,513.11%-294.27K | 101.58%61 | -494.80%-3.87K | --981 |
| Depreciation and amortization | --103.1K | --0 | --0 | ---- | ---- |
| Other non cash items | 477.52%115.5K | -93.25%20K | 997.95%296.35K | -70.24%26.99K | --90.69K |
| Change In working capital | -514.28%-1.12M | -128.30%-182.33K | 980.99%644.39K | 161.57%59.61K | ---96.82K |
| -Change in receivables | ---217.84K | --0 | 200.00%928 | ---928 | --0 |
| -Change in inventory | -388.21%-60.38K | 17,214.88%20.95K | 100.57%121 | ---21.07K | --0 |
| -Change in prepaid assets | 16.03%-231.31K | -12,707.60%-275.48K | --2.19K | --0 | ---- |
| -Change in payables and accrued expense | -1,785.95%-572.25K | -94.71%33.94K | 685.62%641.16K | 184.29%81.61K | ---96.82K |
| -Change in other working capital | -200.00%-38.25K | --38.25K | ---- | ---- | ---- |
| Cash from discontinued investing activities | |||||
| Operating cash flow | -49.46%-6.25M | -416.61%-4.18M | -37.09%-809.07K | 20.74%-590.19K | ---744.61K |
| Investing cash flow | |||||
| Cash flow from continuing investing activities | -552.71%-1.16M | -178.4K | 0 | ||
| Net PPE purchase and sale | ---952.5K | --0 | --0 | ---- | ---- |
| Net intangibles purchase and sale | -18.81%-211.95K | ---178.4K | --0 | ---- | ---- |
| Cash from discontinued investing activities | |||||
| Investing cash flow | -552.71%-1.16M | ---178.4K | --0 | ---- | ---- |
| Financing cash flow | |||||
| Cash flow from continuing financing activities | -87.96%1.65M | 1,583.33%13.69M | 38.96%813.21K | -16.95%585.2K | 704.64K |
| Net issuance payments of debt | -241.04%-206.27K | 46.25%146.25K | --100K | --0 | ---- |
| Net common stock issuance | -100.00%234 | 2,527.79%13.65M | --519.61K | ---- | ---- |
| Proceeds from stock option exercised by employees | --1.87M | --0 | --0 | ---- | ---- |
| Net other financing activities | 83.61%-18.3K | -157.67%-111.65K | -66.92%193.59K | -16.95%585.2K | --704.64K |
| Cash from discontinued financing activities | |||||
| Financing cash flow | -87.96%1.65M | 1,583.33%13.69M | 38.96%813.21K | -16.95%585.2K | --704.64K |
| Net cash flow | |||||
| Beginning cash position | 42,888.32%9.35M | 23.47%21.76K | -22.06%17.62K | -63.87%22.61K | --62.58K |
| Current changes in cash | -161.77%-5.76M | 225,553.74%9.33M | 182.90%4.14K | 87.52%-4.99K | ---39.97K |
| End cash Position | -61.62%3.59M | 42,888.32%9.35M | 23.47%21.76K | -22.06%17.62K | --22.61K |
| Free cash flow | -70.06%-7.41M | -438.66%-4.36M | -37.09%-809.07K | 20.74%-590.19K | ---744.61K |
| Currency Unit | USD | USD | USD | USD | USD |
| Audit Opinions | Unqualified Opinion | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | -- | -- |
Heat List
US
Overall
Symbol
Price
% Chg
No Data
